Skip to Content
Søg Menu

ASCO 2019: Promising new data for patients with relapsed/refractory follicular lymphoma

In this MEDtalk Catherine Diefenbach presents a pre-planned interim analysis of the safety/efficacy of induction and maintenance with Polatuzumab vedotin (Pola) + obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

The Potential of Nanopore Sequencing to Profile Lymphoproliferative Malignancies and Other Neoplasms

/ Marcus Høy Hansen
LymfomMyelomatose
Martin Hutchings

Promising Findings for R/R Large B-Cell Lymphoma – Glofitama and Epcoritamab Show Curative Potential

/ Martin Hutchings
ASCO23B-celle lymfomEHA23Lymfom Play the Video 04:16

Ibrutinib added to Standard-of-Care Therapy improves PFS by 50% for Older Patients with Newly Diagnosed Mantle Cell Lymphoma

/ BestPractice Nordic
ASCO22Lymfom

ASCO 2019: Meet the unique needs of older patients with cancer

/ William Dale
ASCO19Cancer Play the Video 1:17

ASCO 2019: A new potential de-escalation standard neoadjuvant treatment of HER2-positive breast cancer

/ Theodoros Foukakis
HER2ASCO19Brystcancer Play the Video 2:09

ASCO 2019: New standard first-line therapy for EGFR mutant NSCLC

/ Bjørn Henning Grønberg
NSCLCASCO19 Play the Video 1:39

ASCO 2019: New promising drug for second-line SCLC patients

/ Bjørn Henning Grønberg
ASCO19Lungecancer Play the Video 2:32

ASCO 2019: Flere interessante opfølgende studier af lungecancer

/ Odd Terje Brustugun
ASCO19Lungecancer Play the Video 3:40

ASCO 2019: Highlights from ASCO about prostate and kidney cancer

/ Daniel Heinrich
ASCO19ProstatacancerNyrecancer Play the Video 4:32
Back to top